{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:26:56Z","timestamp":1793824016626,"version":"4.6.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12072-023-10543-8","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T10:02:11Z","timestamp":1684490531000},"page":"773-791","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":187,"title":["An international multidisciplinary consensus statement on MAFLD and the risk of CVD"],"prefix":"10.1007","volume":"17","author":[{"given":"Xiao-Dong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virend","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Anwar A.","family":"Chahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Brotons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George V.","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahum","family":"M\u00e9ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleh A.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Cortez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"de Knegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponsiano","family":"Ocama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang Won","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignatios","family":"Ikonomidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sombat","family":"Treeprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lupsor-Platon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik","family":"Ghazinyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Boursier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Hamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George Boon-Bee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamun","family":"Al Mahtab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanka","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-2631","authenticated-orcid":false,"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"10543_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"Z Younossi","year":"2016","unstructured":"Younossi Z, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, MD) 2016;64:73\u201384","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10543_CR2","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology (Baltimore, MD) 2018;67:328\u2013357","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10543_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202\u2013209","journal-title":"J Hepatol"},{"key":"10543_CR4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S2468-1253(22)00127-3","volume":"7","author":"XL Zhang","year":"2022","unstructured":"Zhang XL, Fan JG, Wei L, Shi JP, Zheng MH. Promoting the term MAFLD: China in action. Lancet Gastroenterol Hepatol 2022;7:598","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10543_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1","journal-title":"Gastroenterology"},{"key":"10543_CR6","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1097\/CM9.0000000000000981","volume":"133","author":"KI Zheng","year":"2020","unstructured":"Zheng K, et al. From NAFLD to MAFLD: a \u201credefining\u201d moment for fatty liver disease. Chin Med J 2020;133:2271\u20132273","journal-title":"Chin Med J"},{"key":"10543_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/liv.14739","volume":"41","author":"Y Fouad","year":"2021","unstructured":"Fouad Y, et al. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int 2021;41:255\u2013260","journal-title":"Liver Int"},{"key":"10543_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.21037\/hbsn-21-352","volume":"10","author":"TY Wang","year":"2021","unstructured":"Wang T, George J, Zheng M. Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. Hepatobiliary Surg Nutr 2021;10:849\u2013852","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10543_CR9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","volume":"17","author":"H Tilg","year":"2020","unstructured":"Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 2020;17:387\u2013388","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10543_CR10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","volume":"21","author":"XD Zhou","year":"2022","unstructured":"Zhou XD, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovasc Diabetol 2022;21:270","journal-title":"Cardiovasc Diabetol"},{"key":"10543_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/liv.15142","volume":"42","author":"W Chan","year":"2022","unstructured":"Chan W, Wong V. Meaning of non-overlapping patients between the MAFLD and NAFLD definitions. Liver Int 2022;42:271\u2013273","journal-title":"Liver Int"},{"key":"10543_CR12","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.cgh.2020.10.046","volume":"19","author":"VW Wong","year":"2021","unstructured":"Wong VW, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol 2021;19:2161-2171.e5","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154433","volume":"115","author":"DQ Sun","year":"2021","unstructured":"Sun DQ, et al. MAFLD and risk of CKD. Metabolism 2021;115: 154433","journal-title":"Metabolism"},{"key":"10543_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2020.12.016","volume":"74","author":"KI Zheng","year":"2021","unstructured":"Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol 2021;74:989\u2013991","journal-title":"J Hepatol"},{"key":"10543_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S1470-2045(22)00606-4","volume":"23","author":"M Das","year":"2022","unstructured":"Das M. WHO urges immediate action to tackle non-communicable diseases. Lancet Oncol 2022;23:1361","journal-title":"Lancet Oncol"},{"key":"10543_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"J Lazarus","year":"2022","unstructured":"Lazarus J, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022;19:60\u201378","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10543_CR17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41591-020-0803-x","volume":"26","author":"F Rubino","year":"2020","unstructured":"Rubino F, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26:485\u2013497","journal-title":"Nat Med"},{"key":"10543_CR18","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341\u20131350","journal-title":"N Engl J Med"},{"key":"10543_CR19","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","volume":"69","author":"G Targher","year":"2020","unstructured":"Targher G, Byrne C, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut 2020;69:1691\u20131705","journal-title":"Gut"},{"key":"10543_CR20","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"J Toh","year":"2022","unstructured":"Toh J, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2022;20:2462-2473.e10","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR21","doi-asserted-by":"publisher","first-page":"33386","DOI":"10.1038\/srep33386","volume":"6","author":"S Wu","year":"2016","unstructured":"Wu S, et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 2016;6:33386","journal-title":"Sci Rep"},{"key":"10543_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 2021;6:578\u2013588","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10543_CR23","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:903\u2013913","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10543_CR24","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/hep4.1155","volume":"2","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, et al. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. Hepatol Commun 2018;2:376\u2013392","journal-title":"Hepatol Commun"},{"key":"10543_CR25","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1007\/s10620-022-07508-6","volume":"67","author":"H Kim","year":"2022","unstructured":"Kim H, et al. MAFLD predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci 2022;67:4919","journal-title":"Dig Dis Sci"},{"key":"10543_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.693507","volume":"8","author":"Q Huang","year":"2021","unstructured":"Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality? Results from NHANES III. Front Med 2021;8: 693507","journal-title":"Front Med"},{"key":"10543_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach. Hepatol Res 2021;51:1115\u20131128","journal-title":"Hepatol Res"},{"key":"10543_CR28","doi-asserted-by":"publisher","first-page":"968766","DOI":"10.3389\/fendo.2022.968766","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Front Endocrinol (Lausanne) 2022;13:968766","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10543_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00535-021-01828-6","volume":"56","author":"M Yoneda","year":"2021","unstructured":"Yoneda M, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol 2021;56:1022\u20131032","journal-title":"J Gastroenterol"},{"key":"10543_CR30","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol 2021;19:2138-2147.e10","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, et al. Association of MAFLD With diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab 2022;107:88\u201397","journal-title":"J Clin Endocrinol Metab"},{"key":"10543_CR32","doi-asserted-by":"publisher","first-page":"934225","DOI":"10.3389\/fendo.2022.934225","volume":"13","author":"W Wen","year":"2022","unstructured":"Wen W, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: a meta-analysis. Front Endocrinol (Lausanne) 2022;13:934225","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10543_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016;65:589\u2013600","journal-title":"J Hepatol"},{"key":"10543_CR34","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.1038\/s41598-019-47687-3","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep 2019;9:11124","journal-title":"Sci Rep"},{"key":"10543_CR35","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 2021;75:1284\u20131291","journal-title":"J Hepatol"},{"key":"10543_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245762","volume":"16","author":"M Niriella","year":"2021","unstructured":"Niriella M, et al. Outcomes of NAFLD and MAFLD: results from a community-based, prospective cohort study. PLoS ONE 2021;16: e0245762","journal-title":"PLoS ONE"},{"key":"10543_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328224","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Csermely A, Tilg H, Byrne C, Targher G. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals. Gut 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-328224","journal-title":"Gut"},{"key":"10543_CR38","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","volume":"134","author":"H Zhang","year":"2021","unstructured":"Zhang H, Wang Y, Chen C, Lu Y, Wang N. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999\u20132016. Chin Med J 2021;134:1593\u20131601","journal-title":"Chin Med J"},{"key":"10543_CR39","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.5551\/jat.Er19356","volume":"23","author":"K Nishimura","year":"2016","unstructured":"Nishimura K, et al. Predicting coronary heart disease using risk factor categories for a japanese urban population, and comparison with the Framingham risk score: the suita study. J Atheroscler Thromb 2016;23:1138\u20131139","journal-title":"J Atheroscler Thromb"},{"key":"10543_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.dld.2020.12.123","volume":"53","author":"F Angelico","year":"2021","unstructured":"Angelico F, Baratta F, Pastori D, Ben MD. Assessment of hepatic fibrosis in MAFLD: A new player in the evaluation of residual cardiovascular risk? Dig Liver Dis 2021;53:383\u2013384","journal-title":"Dig Liver Dis"},{"key":"10543_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.dld.2020.10.014","volume":"53","author":"Y Schonmann","year":"2021","unstructured":"Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis 2021;53:79\u201385","journal-title":"Dig Liver Dis"},{"key":"10543_CR42","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","volume":"18","author":"F Baratta","year":"2020","unstructured":"Baratta F, et al. Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol 2020;18:2324-2331.e4","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR43","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1111\/jgh.15589","volume":"36","author":"N Tamaki","year":"2021","unstructured":"Tamaki N, et al. Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol 2021;36:2960\u20132966","journal-title":"J Gastroenterol Hepatol"},{"key":"10543_CR44","doi-asserted-by":"publisher","first-page":"786","DOI":"10.5009\/gnl210290","volume":"16","author":"E Han","year":"2022","unstructured":"Han E, et al. Fibrotic burden determines cardiovascular risk among subjects with metabolic dysfunction-associated fatty liver disease. Gut Liver 2022;16:786\u2013797","journal-title":"Gut Liver"},{"key":"10543_CR45","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.3390\/nu12092762","volume":"12","author":"D Ferro","year":"2020","unstructured":"Ferro D, et al. New insights into the pathogenesis of non-alcoholic fatty liver disease: gut-derived lipopolysaccharides and oxidative stress. Nutrients 2020;12:2762","journal-title":"Nutrients"},{"key":"10543_CR46","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/hep.30163","volume":"69","author":"SJ Daniels","year":"2019","unstructured":"Daniels SJ, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology 2019;69:1075\u20131086","journal-title":"Hepatology"},{"key":"10543_CR47","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/gut.2009.203166","volume":"59","author":"J Parkes","year":"2010","unstructured":"Parkes J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010;59:1245\u20131251","journal-title":"Gut"},{"key":"10543_CR48","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.cgh.2020.07.030","volume":"19","author":"NM Meyersohn","year":"2021","unstructured":"Meyersohn NM, et al. Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease. Clin Gastroenterol Hepatol 2021;19:1480-1488.e14","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cca.2017.01.008","volume":"466","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Bakker SJL, Blokzijl H, Dullaart RPF. Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: interrelationship with age. Clin Chim Acta 2017;466:54\u201360","journal-title":"Clin Chim Acta"},{"key":"10543_CR50","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1007\/s10620-021-06954-y","volume":"66","author":"B Zou","year":"2021","unstructured":"Zou B, Yeo Y, Cheung R, Ingelsson E, Nguyen M. Fatty liver index and development of cardiovascular disease: findings from the UK biobank. Dig Dis Sci 2021;66:2092\u20132100","journal-title":"Dig Dis Sci"},{"key":"10543_CR51","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12933-022-01483-y","volume":"21","author":"J Park","year":"2022","unstructured":"Park J, et al. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study. Cardiovasc Diabetol 2022;21:53","journal-title":"Cardiovasc Diabetol"},{"key":"10543_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5009\/gnl210167","volume":"16","author":"JH Moon","year":"2022","unstructured":"Moon JH, Kim W. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease. Gut Liver 2022;16:433\u2013442","journal-title":"Gut Liver"},{"key":"10543_CR53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3350\/cmh.2021.0406","volume":"28","author":"ASP Tang","year":"2022","unstructured":"Tang ASP, et al. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: an updated meta-analysis with 135,602 individuals. Clin Mol Hepatol 2022;28:483\u2013496","journal-title":"Clin Mol Hepatol"},{"key":"10543_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269265","volume":"17","author":"R Bessho","year":"2022","unstructured":"Bessho R, et al. A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS ONE 2022;17: e0269265","journal-title":"PLoS ONE"},{"key":"10543_CR55","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s11684-021-0888-8","volume":"16","author":"J Wang","year":"2022","unstructured":"Wang J, et al. New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study. Front Med 2022;16:714\u2013722","journal-title":"Front Med"},{"key":"10543_CR56","doi-asserted-by":"publisher","first-page":"154779","DOI":"10.1016\/j.metabol.2021.154779","volume":"120","author":"S Liu","year":"2021","unstructured":"Liu S, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism 2021;120:154779","journal-title":"Metabolism"},{"key":"10543_CR57","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1161\/ATVBAHA.122.318661","volume":"43","author":"K Sung","year":"2023","unstructured":"Sung K, et al. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study. Arterioscler Thromb Vasc Biol 2023;43:482","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10543_CR58","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s12072-021-10252-0","volume":"15","author":"H Liu","year":"2021","unstructured":"Liu H, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hep Int 2021;15:1337\u20131346","journal-title":"Hep Int"},{"key":"10543_CR59","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3390\/jcm11071847","volume":"11","author":"T Noda","year":"2022","unstructured":"Noda T, et al. The prevalence of metabolic dysfunction-associated fatty liver disease and its association with physical function and prognosis in patients with acute coronary syndrome. J Clin Med 2022;11:1847","journal-title":"J Clin Med"},{"key":"10543_CR60","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol 2021;19:2172-2181.e6","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR61","doi-asserted-by":"publisher","first-page":"300060521104707","DOI":"10.1177\/03000605211047074","volume":"49","author":"H Gong","year":"2021","unstructured":"Gong H, Liu X, Cheng F. Relationship between non-alcoholic fatty liver disease and cardiac arrhythmia: a systematic review and meta-analysis. J Int Med Res 2021;49:3000605211047074","journal-title":"J Int Med Res"},{"key":"10543_CR62","doi-asserted-by":"publisher","first-page":"1007171","DOI":"10.3389\/fendo.2022.1007171","volume":"13","author":"F Lei","year":"2022","unstructured":"Lei F, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front Endocrinol (Lausanne) 2022;13:1007171","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10543_CR63","doi-asserted-by":"publisher","first-page":"957245","DOI":"10.3389\/fendo.2022.957245","volume":"13","author":"R Decoin","year":"2022","unstructured":"Decoin R, et al. High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation. Front Endocrinol (Lausanne) 2022;13:957245","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10543_CR64","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s12020-019-02070-0","volume":"66","author":"M Borges-Canha","year":"2019","unstructured":"Borges-Canha M, et al. Association between nonalcoholic fatty liver disease and cardiac function and structure-a meta-analysis. Endocrine 2019;66:467\u2013476","journal-title":"Endocrine"},{"key":"10543_CR65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s12072-022-10319-6","volume":"16","author":"J Yong","year":"2022","unstructured":"Yong J, et al. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hep Int 2022;16:269\u2013281","journal-title":"Hep Int"},{"key":"10543_CR66","doi-asserted-by":"publisher","first-page":"935390","DOI":"10.3389\/fendo.2022.935390","volume":"13","author":"D Peng","year":"2022","unstructured":"Peng D, et al. Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology. Front Endocrinol (Lausanne) 2022;13:935390","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10543_CR67","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41575-018-0010-0","volume":"15","author":"Q Anstee","year":"2018","unstructured":"Anstee Q, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2018;15:425\u2013439","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10543_CR68","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jacc.2021.11.007","volume":"79","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, et al. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. J Am Coll Cardiol 2022;79:180\u2013191","journal-title":"J Am Coll Cardiol"},{"key":"10543_CR69","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","volume":"73","author":"EP Stahl","year":"2019","unstructured":"Stahl EP, et al. Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:948\u2013963","journal-title":"J Am Coll Cardiol"},{"key":"10543_CR70","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/jcm10030467","volume":"10","author":"D Niederseer","year":"2021","unstructured":"Niederseer D, Wernly B, Aigner E, Stickel F, Datz C. NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations. J Clin Med 2021;10:467","journal-title":"J Clin Med"},{"key":"10543_CR71","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","volume":"13","author":"M Siddiqui","year":"2015","unstructured":"Siddiqui M, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol 2015;13:1000\u20138.e3","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR72","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"K Cusi","year":"2012","unstructured":"Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711-725.e6","journal-title":"Gastroenterology"},{"key":"10543_CR73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","volume":"82","author":"MA Austin","year":"1990","unstructured":"Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495\u2013506","journal-title":"Circulation"},{"key":"10543_CR74","doi-asserted-by":"publisher","first-page":"11629","DOI":"10.3390\/ijms222111629","volume":"22","author":"J Guti\u00e9rrez-Cuevas","year":"2021","unstructured":"Guti\u00e9rrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci 2021;22:11629","journal-title":"Int J Mol Sci"},{"key":"10543_CR75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","volume":"17","author":"V Ormazabal","year":"2018","unstructured":"Ormazabal V, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018;17:122","journal-title":"Cardiovasc Diabetol"},{"key":"10543_CR76","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/liv.12611","volume":"35","author":"G Goh","year":"2015","unstructured":"Goh G, et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int 2015;35:979\u2013985","journal-title":"Liver Int"},{"key":"10543_CR77","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4254\/wjh.v4.i12.327","volume":"4","author":"P Paschos","year":"2012","unstructured":"Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: implications for treatment. World J Hepatol 2012;4:327\u2013331","journal-title":"World J Hepatol"},{"key":"10543_CR78","doi-asserted-by":"publisher","first-page":"9479456","DOI":"10.1155\/2022\/9479456","volume":"2022","author":"H Attia","year":"2022","unstructured":"Attia H, et al. Chrysin attenuates fructose-induced nonalcoholic fatty liver in rats via antioxidant and anti-inflammatory effects: the role of angiotensin-converting enzyme 2\/angiotensin (1\u20137)\/mas receptor axis. Oxid Med Cell Longev 2022;2022:9479456","journal-title":"Oxid Med Cell Longev"},{"key":"10543_CR79","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/hep.32294","volume":"76","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2022;76:469\u2013482","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10543_CR80","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3390\/ijms22052350","volume":"22","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Dalbeni A. Treatments for NAFLD: state of art. Int J Mol Sci 2021;22:2350","journal-title":"Int J Mol Sci"},{"key":"10543_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.971484","volume":"13","author":"NWS Chew","year":"2022","unstructured":"Chew NWS, et al. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Front Genet 2022;13: 971484","journal-title":"Front Genet"},{"key":"10543_CR82","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1055\/s-0035-1562947","volume":"35","author":"QM Anstee","year":"2015","unstructured":"Anstee QM, Day CP. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin Liver Dis 2015;35:270\u2013290","journal-title":"Semin Liver Dis"},{"key":"10543_CR83","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/hep.24283","volume":"53","author":"S Sookoian","year":"2011","unstructured":"Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883\u20131894","journal-title":"Hepatology"},{"key":"10543_CR84","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2016.12.020","volume":"152","author":"N Simons","year":"2017","unstructured":"Simons N, et al. PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease. Gastroenterology 2017;152:912\u2013913","journal-title":"Gastroenterology"},{"key":"10543_CR85","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/hep4.1183","volume":"2","author":"S R\u00fcschenbaum","year":"2018","unstructured":"R\u00fcschenbaum S, et al. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun 2018;2:798\u2013806","journal-title":"Hepatol Commun"},{"key":"10543_CR86","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/ng.3977","volume":"49","author":"D Liu","year":"2017","unstructured":"Liu D, et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet 2017;49:1758\u20131766","journal-title":"Nat Genet"},{"key":"10543_CR87","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jacbts.2021.04.001","volume":"6","author":"T Kessler","year":"2021","unstructured":"Kessler T, Schunkert H. Coronary artery disease genetics enlightened by genome-wide association studies. JACC Basic Transl Sci 2021;6:610\u2013623","journal-title":"JACC Basic Transl Sci"},{"key":"10543_CR88","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","volume":"126","author":"J Cai","year":"2020","unstructured":"Cai J, et al. Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res 2020;126:679\u2013704","journal-title":"Circ Res"},{"key":"10543_CR89","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/nu14010103","volume":"14","author":"K Dro\u017cd\u017c","year":"2021","unstructured":"Dro\u017cd\u017c K, et al. Metabolic-associated fatty liver disease (MAFLD), diabetes, and cardiovascular disease: associations with fructose metabolism and gut microbiota. Nutrients 2021;14:103","journal-title":"Nutrients"},{"key":"10543_CR90","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jacc.2019.03.024","volume":"73","author":"WHW Tang","year":"2019","unstructured":"Tang WHW, B\u00e4ckhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:2089\u20132105","journal-title":"J Am Coll Cardiol"},{"key":"10543_CR91","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-0038-1675357","volume":"39","author":"C Reinhardt","year":"2019","unstructured":"Reinhardt C. The gut microbiota as an influencing factor of arterial thrombosis. Hamostaseologie 2019;39:173\u2013179","journal-title":"Hamostaseologie"},{"key":"10543_CR92","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol 2020;72:558\u2013577","journal-title":"J Hepatol"},{"key":"10543_CR93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12944-021-01440-w","volume":"20","author":"F Li","year":"2021","unstructured":"Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and meta-analysis. Lipids Health Dis 2021;20:22","journal-title":"Lipids Health Dis"},{"key":"10543_CR94","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279\u2013297","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10543_CR95","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00535-019-01649-8","volume":"55","author":"H Hu","year":"2020","unstructured":"Hu H, et al. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142\u2013158","journal-title":"J Gastroenterol"},{"key":"10543_CR96","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1161\/CIRCRESAHA.120.316242","volume":"127","author":"M Witkowski","year":"2020","unstructured":"Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res 2020;127:553\u2013570","journal-title":"Circ Res"},{"key":"10543_CR97","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388\u2013402","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"10543_CR98","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jceh.2019.02.005","volume":"9","author":"NS Choudhary","year":"2019","unstructured":"Choudhary NS, Duseja A. Screening of cardiovascular disease in nonalcoholic fatty liver disease: whom and how? J Clin Exp Hepatol 2019;9:506\u2013514","journal-title":"J Clin Exp Hepatol"},{"key":"10543_CR99","volume":"14","author":"G Hassen","year":"2022","unstructured":"Hassen G, et al. Nonalcoholic fatty liver disease: an emerging modern-day risk factor for cardiovascular disease. Cureus 2022;14: e25495","journal-title":"Cureus"},{"key":"10543_CR100","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.5114\/amsad.2020.95651","volume":"5","author":"NR Zaidi","year":"2020","unstructured":"Zaidi NR, Gilani SA, Mehboob R, Waseem H, Hassan A. Diagnostic accuracy of carotid intima media thickness by B-mode ultrasonography in coronary artery disease patients. Arch Med Sci Atheroscler Dis 2020;5:e79\u2013e84","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"10543_CR101","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1007\/s00125-013-2898-9","volume":"56","author":"HM den Ruijter","year":"2013","unstructured":"den Ruijter HM, et al. Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative. Diabetologia 2013;56:1494\u20131502","journal-title":"Diabetologia"},{"key":"10543_CR102","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.dld.2021.02.003","volume":"53","author":"T Wu","year":"2021","unstructured":"Wu T, et al. Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease. Dig Liver Dis 2021;53:1610\u20131619","journal-title":"Dig Liver Dis"},{"key":"10543_CR103","first-page":"357","volume":"15","author":"V Pandyarajan","year":"2019","unstructured":"Pandyarajan V, Gish RG, Alkhouri N, Noureddin M. Screening for nonalcoholic fatty liver disease in the primary care clinic. Gastroenterol Hepatol (N Y) 2019;15:357\u2013365","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10543_CR104","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.dld.2021.01.014","volume":"53","author":"S Zelber-Sagi","year":"2021","unstructured":"Zelber-Sagi S, Schonmann Y, Yeshua H, Bentov I. Reply to: \u201cAssessment of hepatic fibrosis in MAFLD: a new player in the evaluation of residual cardiovascular risk?\u201d Dig Liver Dis 2021;53:385\u2013386","journal-title":"Dig Liver Dis"},{"key":"10543_CR105","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","volume":"71","author":"A Srivastava","year":"2019","unstructured":"Srivastava A, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol 2019;71:371\u2013378","journal-title":"J Hepatol"},{"key":"10543_CR106","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"S Harrison","year":"2023","unstructured":"Harrison S, Allen A, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med 2023;29:562\u2013573","journal-title":"Nat Med"},{"key":"10543_CR107","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/liv.15013","volume":"41","author":"J Rivera-Esteban","year":"2021","unstructured":"Rivera-Esteban J, Armandi A, Augustin S, Bugianesi E. Outcomes and potential surrogate markers for future clinical trials of non-alcoholic steatohepatitis cirrhosis. Liver Int 2021;41:1999\u20132008","journal-title":"Liver Int"},{"key":"10543_CR108","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4093\/dmj.2022.0048","volume":"46","author":"XL Zhang","year":"2022","unstructured":"Zhang XL, Wang TY, Targher G, Byrne CD, Zheng MH. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease. Diabetes Metab J 2022;46:391\u2013401","journal-title":"Diabetes Metab J"},{"key":"10543_CR109","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1097\/MEG.0000000000001135","volume":"30","author":"TT Zou","year":"2018","unstructured":"Zou TT, et al. Lifestyle interventions for patients with nonalcoholic fatty liver disease: a network meta-analysis. Eur J Gastroenterol Hepatol 2018;30:747\u2013755","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10543_CR110","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889\u2013919","journal-title":"Hepatol Int"},{"key":"10543_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4747","volume":"372","author":"ML Petroni","year":"2021","unstructured":"Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease. BMJ 2021;372: m4747","journal-title":"BMJ"},{"key":"10543_CR112","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/ajg.2017.371","volume":"112","author":"F Baratta","year":"2017","unstructured":"Baratta F, et al. Adherence to mediterranean diet and non-alcoholic fatty liver disease: effect on insulin resistance. Am J Gastroenterol 2017;112:1832\u20131839","journal-title":"Am J Gastroenterol"},{"key":"10543_CR113","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/nu12061732","volume":"12","author":"F Baratta","year":"2020","unstructured":"Baratta F, et al. Poor adherence to Mediterranean Diet and serum lipopolysaccharide are associated with oxidative stress in patients with non-alcoholic fatty liver disease. Nutrients 2020;12:1732","journal-title":"Nutrients"},{"key":"10543_CR114","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.3390\/biomedicines9121853","volume":"9","author":"C von Loeffelholz","year":"2021","unstructured":"von Loeffelholz C, Roth J, Coldewey SM, Birkenfeld AL. The role of physical activity in nonalcoholic and metabolic dysfunction associated fatty liver disease. Biomedicines 2021;9:1853","journal-title":"Biomedicines"},{"key":"10543_CR115","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/hep.29055","volume":"65","author":"VH Ajmera","year":"2017","unstructured":"Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology 2017;65:2090\u20132099","journal-title":"Hepatology"},{"key":"10543_CR116","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/hep.30170","volume":"69","author":"Y Chang","year":"2019","unstructured":"Chang Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology (Baltimore, MD) 2019;69:64\u201375","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10543_CR117","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.10.039","author":"BA Rice","year":"2022","unstructured":"Rice BA, Naimi TS, Long MT. Nonheavy alcohol use associates with liver fibrosis and nonalcoholic steatohepatitis in the Framingham heart study. Clin Gastroenterol Hepatol 2022. https:\/\/doi.org\/10.1016\/j.cgh.2022.10.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR118","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.cgh.2018.01.026","volume":"16","author":"V Ajmera","year":"2018","unstructured":"Ajmera V, et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. Clin Gastroenterol Hepatol 2018;16:1511-1520.e5","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10543_CR119","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049767","volume":"12","author":"H Jarvis","year":"2022","unstructured":"Jarvis H, et al. Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis. BMJ Open 2022;12: e049767","journal-title":"BMJ Open"},{"key":"10543_CR120","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jacc.2010.01.006","volume":"55","author":"S Costanzo","year":"2010","unstructured":"Costanzo S, Di Castelnuovo A, Donati MB, Iacoviello L, de Gaetano G. Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. J Am Coll Cardiol 2010;55:1339\u20131347","journal-title":"J Am Coll Cardiol"},{"key":"10543_CR121","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","volume":"391","author":"AM Wood","year":"2018","unstructured":"Wood AM, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391:1513\u20131523","journal-title":"Lancet"},{"key":"10543_CR122","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/ejcn.2010.61","volume":"64","author":"B Hansel","year":"2010","unstructured":"Hansel B, et al. Relationship between alcohol intake, health and social status and cardiovascular risk factors in the Urban Paris-Ile-de-France Cohort: is the cardioprotective action of alcohol a myth? Eur J Clin Nutr 2010;64:561\u2013568","journal-title":"Eur J Clin Nutr"},{"key":"10543_CR123","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.amepre.2005.01.011","volume":"28","author":"TS Naimi","year":"2005","unstructured":"Naimi TS, et al. Cardiovascular risk factors and confounders among nondrinking and moderate-drinking US adults. Am J Prev Med 2005;28:369\u2013373","journal-title":"Am J Prev Med"},{"key":"10543_CR124","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3849","volume":"5","author":"KJ Biddinger","year":"2022","unstructured":"Biddinger KJ, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open 2022;5: e223849","journal-title":"JAMA Netw Open"},{"key":"10543_CR125","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1053\/j.gastro.2017.08.012","volume":"153","author":"LB VanWagner","year":"2017","unstructured":"VanWagner LB, et al. Alcohol use and cardiovascular disease risk in patients with nonalcoholic fatty liver disease. Gastroenterology 2017;153:1260-1272.e3","journal-title":"Gastroenterology"},{"key":"10543_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.alcohol.2020.07.010","volume":"89","author":"K Kashiwagi","year":"2020","unstructured":"Kashiwagi K, et al. Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease. Alcohol 2020;89:1\u20137","journal-title":"Alcohol"},{"key":"10543_CR127","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tem.2022.03.005","volume":"33","author":"J Moon","year":"2022","unstructured":"Moon J, et al. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab 2022;33:424\u2013442","journal-title":"Trends Endocrinol Metab"},{"key":"10543_CR128","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/hep.30320","volume":"69","author":"J Yan","year":"2019","unstructured":"Yan J, et al. Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology (Baltimore, MD) 2019;69:2414\u20132426","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10543_CR129","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776\u2013785","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10543_CR130","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018;6:105\u2013113","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10543_CR131","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016;387:679\u2013690","journal-title":"Lancet"},{"key":"10543_CR132","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 2021;384:1113\u20131124","journal-title":"N Engl J Med"},{"key":"10543_CR133","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3390\/metabo11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, et al. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 2021;11:73","journal-title":"Metabolites"},{"key":"10543_CR134","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","volume":"16","author":"AJ Scheen","year":"2020","unstructured":"Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:556\u2013577","journal-title":"Nat Rev Endocrinol"},{"key":"10543_CR135","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:435\u2013447","journal-title":"J Am Coll Cardiol"},{"key":"10543_CR136","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 2019;139:2022\u20132031","journal-title":"Circulation"},{"key":"10543_CR137","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:422\u2013434","journal-title":"J Am Coll Cardiol"},{"key":"10543_CR138","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1210\/jc.2011-2260","volume":"97","author":"J Bolinder","year":"2012","unstructured":"Bolinder J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020\u20131031","journal-title":"J Clin Endocrinol Metab"},{"key":"10543_CR139","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","volume":"65","author":"LL Lai","year":"2020","unstructured":"Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. Dig Dis Sci 2020;65:623\u2013631","journal-title":"Dig Dis Sci"},{"key":"10543_CR140","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/metabo11010022","volume":"11","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Petracca G, Csermely A, Beatrice G, Targher G. Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites 2020;11:22","journal-title":"Metabolites"},{"key":"10543_CR141","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297\u20132307","journal-title":"N Engl J Med"},{"key":"10543_CR142","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.116.024863","volume":"135","author":"LH Young","year":"2017","unstructured":"Young LH, et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation 2017;135:1882\u20131893","journal-title":"Circulation"},{"key":"10543_CR143","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.118.034763","volume":"138","author":"LH Young","year":"2018","unstructured":"Young LH, et al. Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. Circulation 2018;138:1210\u20131220","journal-title":"Circulation"},{"key":"10543_CR144","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s13340-018-0360-4","volume":"10","author":"J Meht\u00e4l\u00e4","year":"2019","unstructured":"Meht\u00e4l\u00e4 J, et al. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. Diabetol Int 2019;10:24\u201336","journal-title":"Diabetol Int"},{"key":"10543_CR145","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1753-0407.12833","volume":"11","author":"P Portillo-Sanchez","year":"2019","unstructured":"Portillo-Sanchez P, et al. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial. J Diabetes 2019;11:223\u2013231","journal-title":"J Diabetes"},{"key":"10543_CR146","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/hep4.1723","volume":"5","author":"V Jacques","year":"2021","unstructured":"Jacques V, et al. Deuterium-stabilized (R)-pioglitazone (PXL065) Is responsible for pioglitazone efficacy in NASH yet exhibits little to no PPAR\u03b3 activity. Hepatol Commun 2021;5:1412\u20131425","journal-title":"Hepatol Commun"},{"key":"10543_CR147","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082\u2013e1143","journal-title":"Circulation"},{"key":"10543_CR148","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bcp.14943","volume":"88","author":"D Pastori","year":"2022","unstructured":"Pastori D, et al. Statin liver safety in non-alcoholic fatty liver disease: a systematic review and metanalysis. Br J Clin Pharmacol 2022;88:441\u2013451","journal-title":"Br J Clin Pharmacol"},{"key":"10543_CR149","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","volume":"376","author":"VG Athyros","year":"2010","unstructured":"Athyros VG, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916\u20131922","journal-title":"Lancet"},{"key":"10543_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101816","volume":"46","author":"K Fatima","year":"2021","unstructured":"Fatima K, et al. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;46: 101816","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10543_CR151","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/jgh.14794","volume":"35","author":"S Khoo","year":"2020","unstructured":"Khoo S, et al. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:320\u2013325","journal-title":"J Gastroenterol Hepatol"},{"key":"10543_CR152","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","volume":"20","author":"J Du","year":"2014","unstructured":"Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol 2014;20:569\u2013577","journal-title":"World J Gastroenterol"},{"key":"10543_CR153","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367\u2013378","journal-title":"Gastroenterology"},{"key":"10543_CR154","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jama.2020.12567","volume":"324","author":"DE Arterburn","year":"2020","unstructured":"Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA 2020;324:879\u2013887","journal-title":"JAMA"},{"key":"10543_CR155","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1001\/jama.2021.19569","volume":"326","author":"A Aminian","year":"2021","unstructured":"Aminian A, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA 2021;326:2031\u20132042","journal-title":"JAMA"},{"key":"10543_CR156","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.35003","volume":"5","author":"M Elsaid","year":"2022","unstructured":"Elsaid M, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease. JAMA Netw Open 2022;5: e2235003","journal-title":"JAMA Netw Open"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10543-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10543-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:21:30Z","timestamp":1744201290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10543-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":156,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10543"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10543-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"19 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"George V Papatheodoridis: Advisor: Abbvie, Albireo, Amgen, Dicerna, Gilead, GlaxoSmithKline, Ipsen, Janssen, Novo Nordisk, Roche and Takeda; Lectures: Abbvie, Gilead, GlaxoSmithKline, Ipsen, Novo Nordisk, Sobi; Research grants: Abbvie, Gilead; Investigator in clinical trials: Abbvie, Astellas, Bayer, Eiger, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Noorik, Novartis, Novo Nordisk, Regulus, Roche, Takeda. Giada Sebastiani: Speaker: Merck, Gilead, Abbvie, Novonordisk, Novartis and Pfizer; Advisory board member: Pfizer, Merck, Novonordisk, Gilead and Intercept; Unrestricted research funding: Theratecnologies Inc. Gregory Y. H. Lip: Consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthem. No fees are received personally. GYHL is co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 899871. Jian-Gao Fan: Speaker, a consultant and an advisory for Sanofi, Abbott, EchoSens, Novartis, Hisky, Gilead, Allergan, Terns and MADAUS GMBH. John D. Ryan: None related to MAFLD. Consulting: Bond Biosciences, Pfizer, Gilead; Lectures: Kyowa kirin, Falk. Marat Fudim: Dr Fudim was supported by Bayer. He receives consulting fees from Bayer, Merck, NovoNordisk. Michael D. Shapiro: Research Grants (paid to my institution): AHA, NIH, Amgen, Novartis, Ionis, Esperion; Consultant: Ionis, Novartis, Regeneron; Scientific Advisory Boards: Amgen, Novartis, Precision Bioscience. Mindie H. Nguyen: Last 36\u00a0months: Research support: Pfizer, Enanta, Astra Zeneca, Innogen, Exact Science, CurveBio, Delfi Biotech, Gilead, Exact Sciences, Vir Biotech, Helio Health, National Cancer Institute, Glycotest, B.K. Kee Foundation. Consulting and\/or Advisory Board: Intercept, Exact Science, Gilead, GSK, Eli Lilly, Laboratory of Advanced Medicine, Exelixis Research grants. Ming-Hua Zheng: Lectures: Hisky Medical. Philippe Gabriel Steg: Research grants: Amarin, Bayer, Sanofi, and Servier; Clinical Trials (Steering committee, CEC, DSMB): Amarin, AstraZeneca, Bayer, Bristol-Myers Squibb, Idorsia, Novartis, PhaseBio, Pfizer, Sanofi, Servier; Consulting or speaking: Amarin, Amgen, BMS\/Myokardia, Merck, Novo-Nordisk, Regeneron; Senior Associate Editor at Circulation. Seung Up Kim: He\u00a0has served as an advisory committee member Gilead Sciences, Bayer, Eisai, and Novo Nordisk. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbvie, EchoSens, MSD, Eisai, Otsuka, and Bristol-Myers Squibb. He has also received a research grant from Abbvie and Bristol-Myers Squibb. Vincent Wai-Sun Wong: Consultancy: AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions; Lectures: Abbott, AbbVie, Gilead Sciences, Novo Nordisk; Research grants: Gilead Sciences; Stock: Co-founder of Illuminatio Medical Technology Limited. Wah Kheong Chan: Consultant or advisory board member for Roche, Abbvie, Boehringer Ingelheim and Novo Nordisk; speaker for Viatris and Hisky Medical. Yusuf Yilmaz: He has served as consultant to Cymabay, Zydus, Novo Nordisk, and Echosens. The other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}